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	Combretastatin A-4 (1) is a natural product isolated from the South African bushwillow tree Combretum caffrum and endowed with a powerful inhibitory activity on microtubule formation as well as a related antiangiogenic activity.1-3 As such, 1 has a strong potential in the anticancer therapy. A lot of effort has been done on the development of new derivatives of this compound, in order to improve the properties such as solubility and stability and to understand the structure-activity relationships around this series.4-7 Our group has recently turned its attention to developing a synthetic procedure for combretastatin A-4 performed entirely in flow, which should enable continuous production of this useful compound and its derivatives in significant quantities. The full results of this work will be presented in due course.
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